<DOC>
	<DOCNO>NCT00129935</DOCNO>
	<brief_summary>This prospective , randomised phase III trial , compare efficacy safety profile two type adjuvant chemotherapy regimens HER2 negative , node positive breast cancer patient . Control Arm : This include 4 cycle EC 90/600 mg/m2 day 1 every 3 week , follow 4 cycle T 100 mg/m2 day 1 every 3 week . Experimental Arm : This include 4 cycle ET 90/75 mg/m2 , day 1 every 3 week , follow 4 cycle capecitabine 1250 mg/m2 , twice day , via oral intake , 14 day , one-week rest period . Premenopausal woman hormone receptor positive tumour must receive 5 year tamoxifen end chemotherapy . Postmenopausal woman hormone receptor positive tumour receive tamoxifen aromatase inhibitor ( ) end chemotherapy . Patients may receive radiotherapy clinically indicate . Estimation 5-year disease-free survival control arm 72 % . The experimental arm expect increase 5-year disease-free survival 7 % ( 79 % ) . With alpha error 0.05 80 % power , 592 patient per arm need . Assuming 17 % post-randomization drop-out , 691 patient per arm need .</brief_summary>
	<brief_title>EC ( Epirubicin , Cyclophosphamide ) Followed T ( Docetaxel ) Versus ET ( Epirubicin , Docetaxel ) Followed X ( Capecitabine ) Adjuvant Chemotherapy Node Positive Operable Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Written inform consent . Histological diagnosis operable invasive adenocarcinoma breast ( T1T3 ) . Tumours must HER2 negative . Time window surgery study randomization must less 60 day . Surgery must consist mastectomy conservative surgery axillary lymph node dissection . Margins free disease ductal carcinoma situ ( DCIS ) require . Lobular carcinoma consider positive margin . Positive axillary lymph node define least 1 10 node presence disease . If sentinel node technique use , sentinel node node affect . Patients belong follow classification eligible : pN1a , pN2a , pN3a . Status hormone receptor primary tumour . Results must available end adjuvant chemotherapy . Patients must present evidence metastatic disease . Status HER2 primary tumour , know randomization . Patients immune histochemistry ( IHC ) 0 +1 eligible . For patient ICH 2+ , fluorescence situ hybridization ( FISH ) mandatory result must negative . Age &gt; = 18 &lt; = 70 year old . Performance status ( Karnofsky index ) &gt; = 80 . Normal electrocardiogram ( EKG ) 12 week prior randomization . If need , normal cardiac function must confirm leave ventricular ejection fraction ( LVEF ) . Laboratory result ( within 14 day prior randomization ) : Hematology : neutrophil &gt; = 1.5 x 10^9/l ; platelet &gt; = 100 x 10^9/l ; hemoglobin &gt; = 10 mg/dl ; Hepatic function : total bilirubin &lt; = 1 upper normal limit ( UNL ) ; SGOT SGPT &lt; = 2.5 UNL ; alkaline phosphatase &lt; = 2.5 UNL . If value SGOT SGPT &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL , patient eligible ; Renal function : creatinine &lt; = 175 mmol/l ( 2 mg/dl ) ; creatinine clearance &gt; = 60 ml/min ; Pharmacogenetics : one blood sample need SNP assessment . Complete stage workup 12 week prior randomization ( mammogram allow within 20 week window ) . All patient must bilateral mammogram , thorax xray , abdominal echography and/or compute tomography ( CT ) scan . If bone pain , and/or alkaline phosphatase elevation , bone scintigraphy mandatory . This test recommend patient . Other test : clinically indicate . Patients able comply treatment study followup . Negative pregnancy test do 14 prior day randomization . Prior systemic therapy breast cancer . Prior therapy anthracyclines taxanes ( paclitaxel docetaxel ) malignancy . Prior radiotherapy breast cancer . Bilateral invasive breast cancer . Pregnant lactating woman . Adequate contraceptive method must use chemotherapy hormone therapy treatment . Any T4 M1 tumour . Axillary lymph node : patient belong follow classification exclude : pN1b , pN1c , pN2b , pN3b , pN3c . HER2 positive breast cancer ( IHC 3+ positive FISH result ) . Preexisting grade &gt; = 2 motor sensorial neurotoxicity ( National Cancer Institute Common Toxicity Criteria version 2.0 [ NCI CTC v2.0 ] ) . Any serious medical pathology , congestive heart failure ; unstable angina ; history myocardial infarction previous year ; uncontrolled HA high risk arrhythmias . History neurological psychiatric disorder , could preclude patient free informed consent . Active uncontrolled infection . Active peptic ulcer ; unstable diabetes mellitus . Previous current history neoplasms different breast cancer , except skin carcinoma , cervical situ carcinoma , tumour curatively treat without recurrence last 10 year ; ductal situ carcinoma breast ; lobular situ carcinoma . Chronic treatment corticosteroid . Contraindications corticosteroid administration . Concomitant treatment raloxifene , tamoxifen selective estrogen receptor modulators ( SERMs ) , either osteoporosis treatment prevention . These treatment must stop randomisation . Concomitant treatment investigational product ; participation clinical trial nonmarketed drug 20 previous day randomization . Concomitant treatment another therapy cancer . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>HER2 negative breast cancer</keyword>
	<keyword>Node positive breast cancer</keyword>
	<keyword>Adjuvant treatment</keyword>
	<keyword>Oral chemotherapy</keyword>
</DOC>